GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GI Innovation Inc (XKRX:358570) » Definitions » Loans Receivable

GI Innovation (XKRX:358570) Loans Receivable : ₩0.00 Mil (As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is GI Innovation Loans Receivable?

GI Innovation's Loans Receivable for the quarter that ended in Dec. 2024 was ₩0.00 Mil.


GI Innovation Loans Receivable Historical Data

The historical data trend for GI Innovation's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GI Innovation Loans Receivable Chart

GI Innovation Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Loans Receivable
Get a 7-Day Free Trial - - - - -

GI Innovation Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

GI Innovation Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


GI Innovation Loans Receivable Related Terms

Thank you for viewing the detailed overview of GI Innovation's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


GI Innovation Business Description

Traded in Other Exchanges
N/A
Address
Songpa-daero 167, Room 1116 of A-dong, Songpa-gu, Seoul, KOR, 05855
GI Innovation Inc is a bio-venture company that researches and develops protein new drugs through well-structured translational research. The primary research and development for GI Innovation is immuno-oncology drug and allergy disease and developing a fusion protein using the GI-SMART platform.

GI Innovation Headlines

No Headlines